Earnings Preview: CATX to Report Financial Results Post-market on March 26

Moomoo NewsMar 20 21:00 ET

Perspective Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow JonesMar 19 07:12 ET · Ratings

Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup

Dow JonesMar 17 16:53 ET

Promising Developments and Strategic Trial Design Justify Buy Rating for Perspective Therapeutics

TipRanksMar 17 12:45 ET · Ratings

Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy

MT NewswiresMar 17 07:36 ET

Perspective Therapeutics Announces First Patient Dosed With [212Pb]VMT01 in Combination With Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswireMar 17 07:00 ET